The growth just isn't there — a 3–4% organic grower on 3.2× net leverage re-rates down if the tools recovery stalls
One-line thesis. Revvity is a high-quality, recurring-revenue diagnostics and life-sciences-tools franchise that is executing fine operationally — beating its own quarterly numbers — but is growing only 3–4% organically, carries 3.2× net-debt/EBITDA, and already trades roughly in line with a fair value, so there is no obvious edge: a Watch, not a buy, until either growth reaccelerates or the price offers a real margin of safety.
◆ Synthos call — HoldRVTY is a solid business largely reflected at ~$116 — fine to keep, no reason to chase; it gets interesting again below ~$99.
Downside Risk (lower = safer)
6/10 · High
Net-debt/EBITDA 3.2× and 54× trailing GAAP EPS, but low-cyclicality recurring diagnostics base and beta ~1.1.
Growth Quality
5/10 · Moderate
Only 3-4% organic growth, margins compressing YoY, ROIC ~3% — a stalled compounder, not a grower.
Exponential Potential
3/10 · Low
Low-single-digit growth that is flat-to-decelerating; no acceleration and a mature ~$3B TAM position — not exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 3%/yrTo justify today’s $114, earnings would have to compound roughly 3% a year for 10 years (9% discount rate). Analysts forecast ~24%/yr, so the market is pricing in LESS than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Revvity (used to be called PerkinElmer) sells two things: medical tests that screen newborns and pregnant mothers for genetic diseases (its Diagnostics business), and the instruments, reagents and software that laboratories and drug companies use to do research (its Life Sciences business). A lot of that revenue is recurring — labs keep buying the consumables — which makes the business sturdy.
The problem isn't quality, it's speed. The company is only growing sales about 3–4% a year right now — barely faster than inflation — and it borrowed money for past acquisitions, so it owes a fair amount. The stock already trades at about what we think it's worth, so you're not getting a bargain to compensate for the slow growth.
Our verdict is Watch — a good company we'd want to own at the right price or if growth picks up, but not something to chase today.
Here's what the three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The business itself is steady, but it carries meaningful debt and the stock isn't cheap, so a disappointment would hurt.
Growth Quality 5/10 (middling). A solid, profitable business — but it has basically stopped growing, and its profit margins slipped a little this year.
Exponential Potential 3/10 (low). This is a mature, slow-grower. Do not expect it to multiply your money; expect steady, modest results at best.
The one big worry: the growth simply isn't accelerating. If the lab-tools market recovery that everyone is waiting for stalls, a 3–4% grower carrying debt can quietly lose value.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = RVTY · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$113.76
Market cap$13B
P/E trailing5×
P/E FY26E / FY27E22× / 20×
EV / Sales5.2×
EV / EBITDA19.6×
Gross margin51.4%
Net margin8.3%
Dividend yield0.25%
Beta1.107
52-wk range$82 – $118
RSI(14)71
50 / 200-DMA$98 / $97
12-mo return+15% (SPY +21%)
Street target$111 ($95–$124)
Analyst grades15 Buy · 14 Hold · 0 Sell
FMP ratingB
Next earnings2026-08-05
What the experts actually said 0 traceable claims on RVTY · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Revvity, Inc. (NYSE: RVTY) is a Waltham, Massachusetts health-sciences company founded in 1937. It renamed from PerkinElmer in April 2023 after selling off its slower-growth analytical and applied-markets businesses to reposition as a higher-margin diagnostics and life-sciences franchise. Fiscal year ends in late December.
Today the company runs two reporting segments of near-equal size:
Diagnostics — newborn and prenatal screening (Down syndrome, hypothyroidism, muscular dystrophy, metabolic disorders), infectious-disease testing, and genomics/immunodiagnostics reagents and platforms. This is the more defensive, recurring end.
Life Sciences — instruments, reagents, informatics and software (detection, imaging, and genomic workflows) sold to pharma/biotech, academic and government labs, plus contract research services.
Revenue mix (FY2025, from FMP segmentation):
By segment: Life Sciences $1.431B (50%) · Diagnostics $1.425B (50%) — a genuinely balanced two-legged business.
By geography (as reported): United States $1.126B (~39%) · China $425M · Germany $178M · United Kingdom $127M · "Other International" $2.73B. (FMP's geo buckets overlap oddly — "Other International" appears to aggregate most ex-US regions; treat the US ~39% figure as the reliable anchor.) The business is more internationally diversified than a typical US med-tech, which cuts both ways: less US-pricing risk, more FX and China exposure.
The strategic story management is telling right now is portfolio pruning: in Q1'26 it announced the intended divestiture of its China Immunodiagnostics business (~6% of FY25 revenue), and all forward guidance is now given "pro forma" to exclude it — a deliberate trade of revenue for growth-rate and margin quality (see §9).
2. The expert thesis (traceable)
There is no expert coverage of RVTY in the Synthos knowledge base. total_claims = 0; net-bullish voices = 0. No independent analyst, podcaster, or investor in our tracked panel has made a traceable, dated claim on this name.
That means there is no borrowed conviction here, and none is fabricated. Per house standard, when the KB is empty the verdict is explicitly fundamentals- and quant-driven — built from the reported financials, live analyst estimates, valuation, technicals and management's own guidance, all of which are cited from the data files. Read the scores in §3 as a quantitative read, not as an echo of expert enthusiasm that does not exist.
The Street's sell-side view (distinct from the Synthos expert KB) is mildly constructive: 15 Buy / 14 Hold / 0 Sell, consensus price target $110.57 — essentially "hold, fairly valued." We show that as context in §6, not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Above-average
Sturdy, low-cyclicality recurring base and beta ~1.1, but net-debt/EBITDA 3.2× is real leverage, 54× trailing GAAP EPS is optically rich, and a 43% peak-to-trough drawdown history shows it can be sold hard.
Growth Quality
5 · Middling
Only 3–4% organic growth, adjusted operating margin compressed YoY (23.6% vs 25.6% in Q1), ROIC ~2.9% and ROE ~3.3% — recurring revenue and 51% gross margin keep it respectable, but this is a stalled compounder.
Exponential Potential
3 · Low
Low-single-digit growth that is flat-to-decelerating, no positive acceleration, and a mature category position — the multibagger math simply isn't here.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
Case
Key assumptions
Fair value
Bull
Life-sciences tools/pharma-funding cycle turns; organic growth reaccelerates to mid-to-high single digits; China divestiture completes cleanly and lifts the growth rate & margin. FY27E adj EPS beats to ~$6.10; multiple re-rates to ~24.5×.
~$150 (+32%)
Base(our anchor)
Guidance roughly holds — FY26E adj EPS ~$5.25, FY27E ~$5.82; a 3–5% organic grower with recurring revenue earns a ~20× forward multiple.
Synthos fair value = the base case, ~$116 (+2%), with the full $82–$150 span as the honest range. Our base sits almost exactly on the Street's $110.57 consensus and near its $115 median — this is a name where we and the sell-side agree it is fairly, not attractively, priced.This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). RVTY is neither an exponential nor, right now, even a fast compounder:
Forward growth: revenue CAGR FY25→FY30E is only ~4.1% ($2.856B → $3.488B on consensus). EPS grows faster (adj EPS ~$5.25 FY26E → ~$7.14 FY30E, ~8% CAGR) but that is buyback- and mix-driven, not volume-driven.
Acceleration (the 2nd derivative) is flat-to-negative: organic growth is guided at just 3–4% for FY26, versus the high-single-digit/low-double-digit rates the pre-2023 franchise once posted. There is no inflection — the GAAP top line actually shrank from $3.83B (FY21) to $2.86B (FY25) as the company divested and the COVID-diagnostics tailwind rolled off. This is a business being reshaped, not one accelerating.
Room to run: at ~$12.7B market cap in a mature, well-penetrated diagnostics/tools category, there is no under-served TAM that a 3–4% grower is about to capture. The obvious lever is the pharma/academic-funding cycle turning — a cyclical recovery, not a secular expansion.
Reinvestment runway: capex is light (~2.7% of revenue) and FCF is healthy (~$508M FY25), but the capital is going to buybacks and debt rather than into a high-return growth engine — appropriate for a mature name, but the opposite of an exponential's reinvestment story.
Exponential Potential: Low (3/10). Own RVTY, if at all, for steady recurring cash flows and a possible cyclical tools-recovery kicker — not for compounding-at-scale and certainly not for a multibagger. Honest framing: this belongs on a watch-list, not in a growth sleeve.
Revenue: FY25 $2.856B, +3.7% (FY24 $2.755B; FY23 $2.751B). Flat-to-slow after the post-COVID reset (FY21 was $3.83B). Q1'26 revenue $711M, +7% reported / +3% organic YoY.
Margins: gross 51.4% TTM; adjusted operating margin 23.6% in Q1'26, down from 25.6% a year ago — a margin give-back, not expansion. GAAP net margin 8.3% TTM.
Earnings: FY25 GAAP net income $242M, EPS $2.08 (GAAP is depressed by heavy amortization of acquired intangibles). Adjusted EPS is the operative figure: FY25 tracked ~$4.90, and Q4'25/Q1'26 adjusted EPS printed $1.70 / $1.06, both beating Street. The GAAP-vs-adjusted gap is large because goodwill + intangibles are 74% of total assets ($8.96B of $12.17B) from the PerkinElmer-era acquisitions.
Cash flow: FY25 operating CF $582M, capex just −$74M, FCF ~$508M (FCF yield ~3.9%). Clean cash conversion — the recurring model works.
Balance sheet: total debt $3.52B, cash $920M, net debt $2.60B; net-debt/EBITDA 3.2× on TTM EBITDA ~$773M. Investment-grade and serviceable (interest coverage ~3.8×), but this is real leverage for a slow grower — it constrains both M&A optionality and buyback pace.
Share count: down from ~124M (FY23) to ~112M (Q1'26) — an aggressive ~10% reduction funding most of the EPS growth. FY25 alone bought back $821M of stock.
6. Valuation — priced in or room?
RVTY looks expensive on trailing GAAP (54× EPS) but that number is misleading — GAAP EPS is crushed by acquisition amortization. On the adjusted / forward basis the market actually uses, it is reasonable, not cheap:
For a 3–4% organic grower, a ~20× forward multiple is a full-but-fair price — you're paying a quality/recurring-revenue premium, and the PEG is unflattering (mid-teens P/E only pencils out by ~FY29–30). A reverse read: today's ~$114 requires the market to believe the tools cycle turns and the divested/pruned portfolio compounds adjusted EPS at ~8%; if organic growth stays stuck at 3%, the multiple has more room to fall than to rise. Street targets (context): consensus $110.57, median $115, high $124, low $95 — our $116 base fair value sits right in that cluster. This is not a value buy and not a growth buy — it's a fairly-valued hold.
7. Technicals (from the tech block)
Trend:up. $113.76 sits above the 50-DMA ($98.49) and 200-DMA ($96.62), with the 50 above the 200 (golden-cross posture). MACD +4.0 (positive).
Location:−3.4% off the 52-week high ($117.75) and +38% off the 52-week low ($82.26) — near the top of its range. Note the max drawdown of −43% from peak in the tech history: this name has been sold hard before.
Momentum: RSI(14) 71 — overbought (>70). That is a genuine stretched-entry warning: buying here is buying into a short-term extended move.
Relative strength (the tell): RVTY +14.9% 12-mo vs SPY +20.6% and QQQ +30.3% — it has lagged both the market and tech over a year, even though it beat them over the last 3 months (+29% vs SPY +14%). A recent bounce inside a longer stretch of underperformance.
Read: technicals are constructive short-term but overbought, and the 12-month relative-strength picture is underwhelming. No urgency to buy; a pullback toward the rising 50-DMA (~$98) would be a far lower-risk entry than chasing an RSI-71 print.
8. Moat & competitive position
Revvity's moat is moderate and real but not wide: (1) recurring reagent/consumable and screening revenue with switching costs — newborn-screening programs and installed lab instruments generate sticky pull-through; (2) regulatory and public-health entrenchment in newborn/prenatal screening, where accreditation and government relationships are barriers; (3) scale in reagents and genomics workflows. What it lacks is a best-in-class, accelerating product edge — this is a solid franchise in competitive, mature end-markets, not a category-definer.
Peer set (FMP peers, market cap): Exact Sciences $20.0B, Guardant Health $22.3B, Charles River Labs $11.1B, ICON $13.3B, Qiagen $8.3B, Align Technology $13.2B, Solventum $13.6B, Dr. Reddy's $12.0B, Hims & Hers $8.2B, Ensign Group $9.8B. The cleaner comparables are Qiagen and Charles River (tools/diagnostics) — RVTY sits mid-pack on size, with a slower growth rate than the diagnostics high-flyers (EXAS, GH) but higher margins and more recurring revenue than the CRO names. Its ~20× forward multiple is defensible only if the tools cycle turns.
9. Management, capital allocation & guidance
Capital allocation: shareholder-return-tilted — $821M of buybacks in FY25 (~10% of shares retired over two years) plus a small dividend ($0.28/yr, ~0.25% yield, payout ~13%). With net leverage at 3.2×, buybacks (not new M&A) are the primary lever, which is a sensible but growth-limited posture.
Portfolio strategy: the Q1'26 intention to divest the China Immunodiagnostics business (~6% of FY25 revenue) is the key management action — a deliberate trade of revenue for a higher structural growth rate and cleaner margin. Definitive agreement was expected in Q2'26, close in 2027. Execution risk and dilution-to-scale are the watch-items.
Insider activity: the sampled window (through 2026-06-17) shows routine director equity awards (grants, price $0) and a tiny in-kind tax withholding by an officer — no discretionary open-market selling cluster and no alarming signal.
Management's own guidance (half-weighted — their self-interested words): per the SEC 8-K earnings release (filed 2026-05-05), for full-year 2026 on a pro forma basis management forecasts total revenue $2.81–$2.84B, pro forma organic revenue growth 3–4%, and pro forma adjusted EPS $5.20–$5.30. CEO Prahlad Singh characterized Q1 organic growth and adjusted EPS as "exceeding our expectations." We take this at half-weight (management talks its own book): the beat-and-hold pattern is credible, but the headline is still only 3–4% organic growth — management's own numbers confirm the core problem, not a hidden acceleration.
10. Catalysts & what to watch
Next earnings: 2026-07-27 (Q2'26; Street EPS $1.23, revenue ~$703M). Watch organic growth (does it beat the 3–4% guide?) and adjusted operating margin (does the YoY compression reverse?).
China Immunodiagnostics divestiture: definitive agreement / close timing and the pro forma growth-and-margin uplift it delivers — the clearest structural catalyst.
Life-sciences tools / pharma & academic funding cycle: the single biggest swing factor for reacceleration. Instrument demand and biotech funding turning up would validate the bull case.
Guidance revisions: any raise to the 3–4% organic guide would re-rate the multiple; a cut would do the reverse.
Deleveraging: progress bringing net-debt/EBITDA below ~3× frees up capital-allocation optionality.
Thesis tripwires (what would change the call): organic growth slipping below ~2% for two quarters; further adjusted-margin compression; the China divestiture falling through or closing dilutively; or the multiple pushing above ~24× forward without a growth reacceleration (which would flip us from Watch toward Avoid).
11. Key risks
Growth stall (the core risk): a 3–4% organic grower has little cushion — if the tools/funding recovery stalls, both estimates and the multiple fall together.
Leverage: net-debt/EBITDA 3.2× is manageable but real; it limits M&A and buyback flexibility and amplifies downside in a de-rating.
Valuation / de-rating: ~20× forward for low-single-digit growth leaves the stock exposed to multiple compression on any disappointment.
GAAP-vs-adjusted gap / intangibles: goodwill + intangibles are 74% of assets; heavy amortization keeps GAAP earnings and ROIC (~3%) optically weak, and any impairment would hit the book.
Macro / tariffs / China: management explicitly flags tariff and global-economic risk; China exposure (~15% of revenue pre-divestiture) adds FX and geopolitical sensitivity.
No expert coverage: zero traceable KB conviction means the thesis rests only on fundamentals and quant — there is no independent panel to corroborate or challenge it.
12. Verdict, position sizing & monitoring
Watch. Revvity is a genuinely good business — recurring diagnostics and life-sciences revenue, 51% gross margins, clean FCF (~$508M), disciplined buybacks — that is simply not growing fast enough to earn its ~20× forward multiple, and it carries 3.2× net leverage while it waits for a tools-market recovery. Our base fair value (~$116) sits essentially on top of the price and the Street consensus, so there is no margin of safety and no obvious edge in buying here. The stock is also technically overbought (RSI 71) and has lagged the market over 12 months. With zero expert coverage in the Synthos KB, there is no conviction case to override the neutral fundamentals.
Sizing:0% today / watch-list. We'd want either (a) a pullback toward the ~$98 rising 50-DMA for a margin of safety, or (b) evidence of organic reacceleration (tools cycle turning, China divestiture lifting the growth rate) before upgrading toward Buy — Tactical.
Monitoring: re-underwrite on the §10 tripwires; formal re-score at the 2026-07-27 print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $113.76.
Single biggest risk: the growth just isn't there — a 3–4% organic grower on 3.2× net leverage re-rates down if the recovery it's priced for fails to arrive.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — no expert coverage exists for RVTY in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no expert conviction is cited or implied, and none is fabricated (claim-ID reconciliation makes fabrication structurally impossible — there are simply no claims to cite).
Data as-of: fundamentals 2026-04-05 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K filed 2026-05-05. Forward figures are analyst consensus (FMP) or management guidance, each labeled as estimates.
Management caveat: FY2026 guidance (pro forma revenue $2.81–$2.84B, organic +3–4%, adj EPS $5.20–$5.30) is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").